A new nasal and needle-free Covid-19 vaccine, licensed to Hyderabad-based Indian Immunologicals, is poised to be a game changer in the fight against the virus, according to research released on Tuesday. A novel nasal and needle-free Covid-19 vaccine, licenced to Hyderabad-based Indian Immunologicals, is set to be a game changer against the infectious disease, according to research on Tuesday. The study led by a team from Griffith University in Australia investigated the effectiveness of administering a Covid vaccination -- CDO-7N-1 -- through the nasal passages.
“This is a live attenuated intranasal vaccine, called CDO-7N-1, designed to be administered intranasally, thereby inducing potential mucosal immunity as well as systemic immunity with just a single dose,” said Professor Suresh Mahalingam of Griffith's Institute for Biomedicine and Glycomics. The research, published in the journal, Nature Communications, showed the vaccine induces strong memory responses in the nasal mucosa offering long-term protection for up to a year or more. “It’s been designed to be administered as a single dose, ideally as a booster vaccine, as a safe alternative to needles with no adverse reactions in the short or long term,” Mahalingam said.
Compared to alternative vaccination strategies, live-attenuated vaccines provide several important advantages. Their effects on humoral and cellular immunity are strong and persistent, but they frequently require a dose. Unlike many other vaccine .